Cargando…
Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369398/ https://www.ncbi.nlm.nih.gov/pubmed/37502699 http://dx.doi.org/10.1016/j.ctro.2023.100653 |
_version_ | 1785077751728832512 |
---|---|
author | Ehret, Felix Wolfgang, Josy Allwohn, Luisa Onken, Julia Wasilewski, David Roohani, Siyer Oertel, Joachim Zips, Daniel Kaul, David |
author_facet | Ehret, Felix Wolfgang, Josy Allwohn, Luisa Onken, Julia Wasilewski, David Roohani, Siyer Oertel, Joachim Zips, Daniel Kaul, David |
author_sort | Ehret, Felix |
collection | PubMed |
description | PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation. MATERIALS AND METHODS: GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis. RESULTS: A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis. CONCLUSION: The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis. |
format | Online Article Text |
id | pubmed-10369398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103693982023-07-27 Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation Ehret, Felix Wolfgang, Josy Allwohn, Luisa Onken, Julia Wasilewski, David Roohani, Siyer Oertel, Joachim Zips, Daniel Kaul, David Clin Transl Radiat Oncol Original Research Article PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation. MATERIALS AND METHODS: GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis. RESULTS: A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis. CONCLUSION: The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis. Elsevier 2023-06-13 /pmc/articles/PMC10369398/ /pubmed/37502699 http://dx.doi.org/10.1016/j.ctro.2023.100653 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Ehret, Felix Wolfgang, Josy Allwohn, Luisa Onken, Julia Wasilewski, David Roohani, Siyer Oertel, Joachim Zips, Daniel Kaul, David Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation |
title | Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation |
title_full | Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation |
title_fullStr | Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation |
title_full_unstemmed | Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation |
title_short | Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation |
title_sort | outcomes of isocitrate dehydrogenase wild type glioblastoma after re-irradiation |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369398/ https://www.ncbi.nlm.nih.gov/pubmed/37502699 http://dx.doi.org/10.1016/j.ctro.2023.100653 |
work_keys_str_mv | AT ehretfelix outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT wolfgangjosy outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT allwohnluisa outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT onkenjulia outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT wasilewskidavid outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT roohanisiyer outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT oerteljoachim outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT zipsdaniel outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation AT kauldavid outcomesofisocitratedehydrogenasewildtypeglioblastomaafterreirradiation |